Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 15/2002

01-10-2002 | Adis New Drug Profile

Biapenem

A Viewpoint by Erik Nord

Author: Erik Nord

Published in: Drugs | Issue 15/2002

Login to get access

Excerpt

Biapenem is a new carbapenem antibacterial agent. It has a triazolium group and a β-methyl substitution at C-1 on the carbapenem nucleus to reduce the ability of dihydropeptidase-I (DHP-I) to attack the β-lactam molecule. …
Metadata
Title
Biapenem
A Viewpoint by Erik Nord
Author
Erik Nord
Publication date
01-10-2002
Publisher
Springer International Publishing
Published in
Drugs / Issue 15/2002
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200262150-00007

Other articles of this Issue 15/2002

Drugs 15/2002 Go to the issue

Adis New Drug Profile

Extended-Release Methylphenidate (Ritalin® LA)

Leading Article

HMG- CoA Reductase Inhibitors as Immunomodulators

Adis New Drug Profile

Gefitinib

Adis New Drug Profile

Gefitinib

Adis New Formulation Profile

Extended- Release Methylphenidate (Ritalin® LA)

Therapy in Practice

Pharmacological Strategies to Decrease Transfusion Requirements in Patients Undergoing Surgery